Genprex R&D Spending Growth & History (GNPX)
Genprex's r&d spending was $9.4M for fiscal 2025.
View full Genprex company overviewGenprex annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $9.4M | −$1.1M | −10.50% |
| 2024 | 2024-12-31 | $10.5M | −$7.1M | −40.20% |
| 2023 | 2023-12-31 | $17.6M | $6.1M | +53.05% |
| 2022 | 2022-12-31 | $11.5M | $2.5M | +28.31% |
| 2021 | 2021-12-31 | $9.0M | $1.7M | +22.84% |
| 2020 | 2020-12-31 | $7.3M | $5.3M | +271.27% |
| 2019 | 2019-12-31 | $2.0M | $995,580 | +102.49% |
| 2018 | 2018-12-31 | $971,427 | $681,493 | +235.05% |
| 2017 | 2017-12-31 | $289,934 | −$64,949 | −18.30% |
| 2016 | 2016-12-31 | $354,883 | — | — |
Genprex quarterly r&d spending
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.7M | $183,976 | +7.36% |
| Q1 2026 | 2026-03-31 | $2.7M | $205,952 | +8.11% |
| Q4 2025 | 2025-12-31 | $2.2M | −$642,112 | −22.62% |
| Q3 2025 | 2025-09-30 | $2.2M | −$563,200 | −20.43% |
| Q2 2025 | 2025-06-30 | $2.5M | $832,973 | +49.98% |
| Q1 2025 | 2025-03-31 | $2.5M | −$734,387 | −22.43% |
| Q4 2024 | 2024-12-31 | $2.8M | −$874,531 | −23.55% |
| Q3 2024 | 2024-09-30 | $2.8M | −$1.9M | −40.30% |
| Q2 2024 | 2024-06-30 | $1.7M | −$2.3M | −58.10% |
| Q1 2024 | 2024-03-31 | $3.3M | −$2.0M | −38.34% |
| Q4 2023 | 2023-12-31 | $3.7M | $327,803 | +9.68% |
| Q3 2023 | 2023-09-30 | $4.6M | $1.5M | +46.20% |
| Q2 2023 | 2023-06-30 | $4.0M | $1.0M | +35.87% |
| Q1 2023 | 2023-03-31 | $5.3M | $3.3M | +160.27% |
| Q4 2022 | 2022-12-31 | $3.4M | −$587,172 | −14.78% |
| Q3 2022 | 2022-09-30 | $3.2M | $1.7M | +120.51% |
| Q2 2022 | 2022-06-30 | $2.9M | $1.4M | +91.77% |
| Q1 2022 | 2022-03-31 | $2.0M | −$1 | −0.00% |
| Q4 2021 | 2021-12-31 | $4.0M | $1.7M | +71.27% |
| Q3 2021 | 2021-09-30 | $1.4M | $81,983 | +6.07% |
| Q2 2021 | 2021-06-30 | $1.5M | −$629,360 | −29.20% |
| Q1 2021 | 2021-03-31 | $2.0M | $562,349 | +38.05% |
| Q4 2020 | 2020-12-31 | $2.3M | $1.8M | +373.75% |
| Q3 2020 | 2020-09-30 | $1.4M | $882,672 | +188.87% |
| Q2 2020 | 2020-06-30 | $2.2M | $1.7M | +329.38% |
| Q1 2020 | 2020-03-31 | $1.5M | $969,835 | +190.90% |
| Q4 2019 | 2019-12-31 | $489,581 | $172,433 | +54.37% |
| Q3 2019 | 2019-09-30 | $467,344 | −$22,345 | −4.56% |
| Q2 2019 | 2019-06-30 | $502,040 | $389,071 | +344.41% |
| Q1 2019 | 2019-03-31 | $508,042 | $456,421 | +884.18% |
| Q4 2018 | 2018-12-31 | $317,148 | $256,074 | +419.28% |
| Q3 2018 | 2018-09-30 | $489,689 | $434,172 | +782.05% |
| Q2 2018 | 2018-06-30 | $112,969 | $7,990 | +7.61% |
| Q1 2018 | 2018-03-31 | $51,621 | −$16,743 | −24.49% |
| Q4 2017 | 2017-12-31 | $61,074 | — | — |
| Q3 2017 | 2017-09-30 | $55,517 | −$34,379 | −38.24% |
| Q2 2017 | 2017-06-30 | $104,979 | — | — |
| Q1 2017 | 2017-03-31 | $68,364 | — | — |
| Q3 2016 | 2016-09-30 | $89,896 | — | — |
Genprex r&d spending trends
Over the last five fiscal years, Genprex's r&d spending increased from $7.3M to $9.4M, a change of $2.1M. The latest reported quarter, Q2 2026, shows $2.7M.
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Genprex source filings ↗